Below is a list of ways that the FDA has recommended to reduce the occurrences of acetominophen hepatotxicity:
1. Enhance public education efforts (also may reduce intentional overdoses)
- Develop concise, clear messages
- Increase partnerships with other governmental agencies, health professionals, industry, consumers, and media
- Prominently display the name acetaminophen on principal display panel
- Include warning that taking more than recommended amount may cause severe liver injury and should not be used with other products containing acetaminophen (on the container and box)
- Include warning about need for prompt medical attention after acetaminophen overdose even when no symptoms of a health problem are present
- Include warnings for people with liver disease and alcohol users
4. Limit the tablet strength for immediate-release forms to 325 mg, single adult dose to 650 mg, and extended-release forms commensurate with total daily dose.
5. Limit options in pediatric liquid formulations
- Limit pediatric liquid formulation to one mid-strength concentration
- Require that a measuring device be included in each package
- Include dosing instructions for children under 2 years if accurate dosing instructions can be determined.
The Acetaminophen Hepatotoxicity Working Group Center for Drug and Evaluation Research, F. D. (2008). Recommendations for FDA Interventions to Decrease the Occurance of Acetaminophen Hepatotoxicity.